11 May 2020 – update on progress
The company has announced that it has shipped Affimer reagents for Covid-19 antigen testing to its diagnostic test development partners Cytiva and Adeptrix ahead of schedule. Cytiva will work with Avacta to develop a saliva test for mass population screening to diagnose Covid-19 and hopes to have a prototype within a few weeks. Adeptrix is working on another project to develop a Covid-19 laboratory test to run on hospital mass spectrometers. The shares remain a SPECULATIVE BUY.